Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Paul if you think MGC is over valued then sell ASAP instead of waffling on, there are plenty of people out there who will buy your modest holding off you!
More chunky buys
02-Sep-21 16:07:14 2.795 679,572 Buy* 18.99k
02-Sep-21 16:04:57 2.778 746,971 Buy* 20.75k
02-Sep-21 16:28:33 2.791582 2,500,000 Buy* 2.75 2.80 69.79k O
where is the RNS??
Phase III result is the biggie, the link below is the interview with Dr Nadya Lisovoder on the phase II clinical study of 50 patients with moderate COVID-19 symptoms, definitely worth a read.
https://www.yumpu.com/en/document/view/65797234/artemic-interview
plenty more of news to come this month, AMC to get regulatory approval, phase 3 interim results, just be patient cause Mgc is definitely heading in the right direction
The upside here is huge, take GW Pharma as a good example.
GW Pharma is the first company to receive FDA approval for medicine derived from the cannabis plant.
GW Pharmaceuticals stock soared 46% on Wednesday after Jazz Pharma said it would buy the company for $7.2 billion.
The proposed deal will include $200 in cash and $20 in shares of Jazz Pharma, and is expected to close in the second quarter of 2021.
· MGC Pharma has been granted government approval to import its phytomedicine CimetrA™ into India as a final step towards obtaining Emergency Use Authorisation for the treatment of patients with COVID-19.
· Emergency Use Authorisation is the registration process for medicines approved for the treatment of COVID-19 around the world.
· Emergency Use Authorisation would enable MGC Pharma to market and sell CimetrA™ as an approved medicine for the treatment of COVID-19 in India, and potentially in other territories under international Mutual Recognition protocols for medicines.
· Medopharm Private Ltd (Medopharm), one of the leading manufacturers and exporters of pharmaceutical products in India, is managing the Emergency Use Authorisation process for CimetrA™ in India on MGC Pharma's behalf.
· Medopharm has been appointed importer for CimetrA™ in India once the Emergency Use Authorisation has been granted
· CimetrA™ is currently undergoing Phase III trial for the treatment of COVID-19 l in Israel
Fantastic news!
MGC Pharma has been granted government approval to import its phytomedicine CimetrA™ into India as a final step towards obtaining Emergency Use Authorisation for the treatment of patients with COVID-19.
lets get the interim results out ASAP, sitting at 2.6p is a joke
Aren't covid results due in August? Hopefully it will be released next week
lack of patience
3.7 will seem very cheap in the coming months, yesterday's RNS was an absolute game changer